Therefore, this study indicates that KLF5 acetylation is a barrier to tumor progression boosted by PTEN deficiency and provides evidence for a PTM as an essential molecular event induced by PTEN inactivation to stall prostate cancer progression. This evidence concerns the gene KLF5 and neoplasm.